Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Plecanatide - Bausch Health Companies

Drug Profile

Plecanatide - Bausch Health Companies

Alternative Names: GCRA; Guanilib; SP-304; TRULANCE

Latest Information Update: 07 Jun 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Callisto Pharmaceuticals
  • Developer Bausch Health Companies; Cipher Pharmaceuticals; Synergy Pharmaceuticals Inc
  • Class Anti-inflammatories; Irritable bowel syndrome therapies; Laxatives; Peptides
  • Mechanism of Action Guanylate cyclase C agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Constipation; Irritable bowel syndrome
  • Discontinued Inflammatory bowel diseases; Ulcerative colitis

Most Recent Events

  • 10 May 2019 Cipher Pharmaceuticals expects approval for plecanatide in chronic idiopathic Constipation and Irritable bowel syndrome with constipation in Canada in Q4 of 2019
  • 06 Mar 2019 Bausch Health acquires plecanatide and related intellectual property from Synergy Pharmaceuticals
  • 17 Dec 2018 Preregistration for Irritable bowel syndrome in Canada (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top